[{"id":"d4485f54-359c-4ee3-8554-f4f3c66c58bb","acronym":"TNG462-C101","url":"https://clinicaltrials.gov/study/NCT05732831","created_at":"2023-02-17T15:00:50.938Z","updated_at":"2025-02-25T14:41:52.620Z","phase":"Phase 1/2","brief_title":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","source_id_and_acronym":"NCT05732831 - TNG462-C101","lead_sponsor":"Tango Therapeutics, Inc.","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • vopimetostat (TNG462)"],"overall_status":"Recruiting","enrollment":" Enrollment 225","initiation":"Initiation: 05/26/2023","start_date":" 05/26/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-14"},{"id":"6e960e10-a292-4eb9-ac61-0062dbf094ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT05975073","created_at":"2023-08-03T15:09:55.318Z","updated_at":"2024-07-02T16:34:37.673Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors","source_id_and_acronym":"NCT05975073","lead_sponsor":"Amgen","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDE397 • AMG 193"],"overall_status":"Recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 12/03/2026","study_completion_date":" 12/03/2026","last_update_posted":"2024-06-06"},{"id":"a89145ed-d1fb-47bb-8570-547616d247d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05275478","created_at":"2022-03-11T15:53:41.554Z","updated_at":"2024-07-02T16:34:59.862Z","phase":"Phase 1/2","brief_title":"Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors","source_id_and_acronym":"NCT05275478","lead_sponsor":"Tango Therapeutics, Inc.","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNG908"],"overall_status":"Recruiting","enrollment":" Enrollment 192","initiation":"Initiation: 03/23/2022","start_date":" 03/23/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-31"},{"id":"92c00917-1e46-4b94-b994-56d21f87434a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04794699","created_at":"2021-03-12T16:52:33.483Z","updated_at":"2024-07-02T16:35:05.377Z","phase":"Phase 1","brief_title":"Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion","source_id_and_acronym":"NCT04794699","lead_sponsor":"IDEAYA Biosciences","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • docetaxel • albumin-bound paclitaxel • pemetrexed • Trodelvy (sacituzumab govitecan-hziy) • IDE397"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 04/14/2021","start_date":" 04/14/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 03/30/2027","study_completion_date":" 03/30/2027","last_update_posted":"2024-05-07"},{"id":"3c3237ce-b2fe-4d38-831f-297bf37b8861","acronym":"","url":"https://clinicaltrials.gov/study/NCT05312372","created_at":"2022-04-05T13:52:46.118Z","updated_at":"2024-07-02T16:35:59.449Z","phase":"Phase 1/2","brief_title":"S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC","source_id_and_acronym":"NCT05312372","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" PD-L1 • MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["PD-L1 • MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • S095033"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2022-12-07"},{"id":"d1253b91-fc27-48d4-8eda-23186b966e62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03361358","created_at":"2021-01-18T16:35:28.827Z","updated_at":"2024-07-02T16:36:48.342Z","phase":"","brief_title":"Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma","source_id_and_acronym":"NCT03361358","lead_sponsor":"Agios Pharmaceuticals, Inc.","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e S095033"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 09/30/2019","primary_completion_date":" 09/30/2019","study_txt":" Completion: 09/30/2019","study_completion_date":" 09/30/2019","last_update_posted":"2020-03-16"}]